MRS suggests different levels of functionality between IDH mutations, with the IDH2-mutant gliomas demonstrating greater (>3x) increases in 2HG than IDH1-mutant gliomas.25Figure 2. The gene discussed is IDH1; the disease is central nervous system cancer.